Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Accesso Technology at 'buy'

(Sharecast News) - Berenberg initiated coverage of Accesso Technology on Tuesday with a 'buy' rating and 775p price target. "We think that it is well positioned in a large, growing and fragmented market," the bank said.

"Significant operational leverage and a software as a service- (SaaS)-based business model provide scope for upside to accesso's current - relatively low - margin levels. Meanwhile, strong cash-flow generation and surplus cash should provide further upside potential."

It said the company, which provides virtual queuing and ticketing solutions for the global leisure industry, does have underlying exposure to cyclical elements of the leisure industry, which has weighed on its relative rating.

However, Berenberg believes that concerns about US consumer confidence are overdone, and that the market underappreciates Accesso's recent diversification and its long-term growth potential.

It said the recent share price performance has diverged from the underlying performance of the business and the stock now trades at a discount to peers and to its more recent historical average.

"We see this as an attractive entry point into a long-term growth story."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.